Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.

Original languageEnglish (US)
Pages (from-to)1481-1489
Number of pages9
JournalLeukemia Research
Volume36
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Anniversaries and Special Events
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Mutation
Cytogenetics
Neoplasms
Therapeutics
Pharmaceutical Preparations

Keywords

  • Myelodysplastic syndromes (MDS)
  • Myeloproliferative neoplasms (MPN)

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Myeloproliferative neoplasms 2012 : The John M. Bennett 80th birthday anniversary lecture. / Tefferi, Ayalew.

In: Leukemia Research, Vol. 36, No. 12, 12.2012, p. 1481-1489.

Research output: Contribution to journalArticle

@article{739870c0efd74846884cef3ab657a9ca,
title = "Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture",
abstract = "Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.",
keywords = "Myelodysplastic syndromes (MDS), Myeloproliferative neoplasms (MPN)",
author = "Ayalew Tefferi",
year = "2012",
month = "12",
doi = "10.1016/j.leukres.2012.08.011",
language = "English (US)",
volume = "36",
pages = "1481--1489",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Myeloproliferative neoplasms 2012

T2 - The John M. Bennett 80th birthday anniversary lecture

AU - Tefferi, Ayalew

PY - 2012/12

Y1 - 2012/12

N2 - Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.

AB - Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.

KW - Myelodysplastic syndromes (MDS)

KW - Myeloproliferative neoplasms (MPN)

UR - http://www.scopus.com/inward/record.url?scp=84868193850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868193850&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.08.011

DO - 10.1016/j.leukres.2012.08.011

M3 - Article

C2 - 22917768

AN - SCOPUS:84868193850

VL - 36

SP - 1481

EP - 1489

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 12

ER -